dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Küsimustik

Sotsiaalministeerium · 20. juuni 2019
Viit
1.4-5/1660-1
Registreeritud
20. juuni 2019
Dokumendi liik
Sissetulev kiri
Adressaat
WHO
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-5 Rahvusvahelistele organisatsioonidele saadetavad aruanded ja küsimustikud (sotsiaalharta, sotsiaalkindlustuskoodeksi jm aruanded) (Arhiiviväärtuslik)
Toimik
1.4-5/2019
Vastutaja
Tiina Drell (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)

Failid

  • 📎Annex_eng.pdf436 KB
  • 📎E-kiri.pdf466 KB
  • 📎STI Questionnaire 2019 - EST.pdf154 KB
  • 📎STI_Questionnaire_en.pdf363 KB

Sisu (failidest)

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION Date: 19 June 2019 ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ Ms Elen Ohov REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L’EUROPE Adviser REGIONALBÜRO FÜR EUROPA European Union Affairs and International Co- ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО operation Department Head office: Ministry of Social Affairs UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 10122 Tallinn Email: [email protected] Website: http://www.euro.who.int Estonia Our reference: Your reference: Notre référence: Votre référence: Unser Zeichen: Ihr Zeichen: См. наш номер: На Ваш номер: Dear Ms Ohov, Global survey on sexually transmitted infections progress, 2019 WHO is committed to report on the implementation progress of the Global Health Sector Strategy on Sexually Transmitted Infections (STIs) 2016–21. The Global Health Sector Strategy on STIs (resolution WHA69.22) identified milestones for achievement by 2020. Reporting from Member States on these milestones and country progress in implementation will be presented at the World Health Assembly 73 in 2020. We are writing to seek your assistance in providing WHO Regional Office for Europe with information on STI interventions related to the global STI strategy at country level. Please find attached the survey questionnaire entitled “Evaluation of the Global STI Strategy: country STI survey. STI activities assessment at country level.” for submission to the WHO Regional Office for Europe. All the information will be used to develop the 2020 report to the World Health Assembly. Please confirm the receipt of this message and inform us if you have difficulties receiving the attachment. We would be grateful if the completed questionnaire is submitted by e-mail to [email protected] by 12 July 2019. Sincerely yours, Dr Masoud Dara Acting Director Communicable Diseases Department UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark Encls: Questionnaire “Evaluation of the Global STI Strategy: country STI survey. STI activities assessment at country level.” Annex 4. Text for inclusion in data collection forms Copy for information to: Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-Ameerika 1, 10129 Tallinn, Estonia H.E. Mr Andre Pung, Ambassador, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia –2– CPG World Health Evaluation of the Global STI Strategy: Country STI Survey Page 1/1 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 This questionnaire will take approximately 30 minutes to complete. Thank you for taking the time. This information is essential for the assessment of interventions and activities that have taken place since the launching of the Global Strategy on Sexually Transmitted Infections (STI). The information will not only assist WHO in compiling its report to the World Health Assembly, but also countries themselves to understand what has been happening around the prevention and control of STI. The questionnaire will give a high level assessment of STI prevention and control efforts, and identify areas in need of strengthening to achieve maximum coverage of STI prevention and care activities. 1. Name of Country: 2. Name of Person or Persons Completing this Form: 3. Job titles/description: 1= National STI programme director or manager 2= National HIV programme director or manager 3= National sexual and reproductive health officer or director 4= National programme officer for maternal and child health 5= National disease surveillance coordinator 6= National laboratory surveillance officer or manager 7= WHO country programme officer 8= Other UN agency HIV, STI or sexual and reproductive health officer (UNICEF, UNAIDS, UNFPA) 9= Other 3a) If Other , please specify: 4. Address: 5. Telephone number: 6. Mobile number: 7. E-mail address: To be completed by Responder (the responder will consolidate the information if more than one person is involved in the process): Name: Signature: Day Month Year Date: 2 0 1 9 AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 1/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: I - STI strategy 1. Are you familiar with (have a copy or have the link to) the WHO Global Health Sector Strategy on Sexually Transmitted Infections, 2016-2021? 1= Yes 2= No 2. Does the country have an official National STI Strategy? 1= Yes 2= No (Go to Q3) 2a) When was it last updated? (year) 9999 if Don't know or Data not available 2b) Please provide the WEB link of National STI Strategy: 2b1) Provide WEB Link if Available : OR 2b2) Check the box if WEB link is Not available: 2c) Is the National STI Strategy/Programme separate from the National HIV Strategy/Programme? 1= Yes, separate 2= No, integrated with HIV strategy 3= Do not have an STI programme 2d) Was the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 used as a reference to develop or to update the National STI Strategy or Programme? 1= Yes 2= No 3= Don't know 4= Data not available 2e) Has your National STI Strategy/Programme been disseminated and how? 1= Yes 2= No, not formally distributed (Go to Q3) 2e1) Posted on website: 1= Yes 2= No (Go to Q2e2) 2e1s) If Yes , please provide the link: 2e2) Email distribution: 1= Yes 2= No (Go to Q2e3) If Yes , to whom/at what level: Yes No 2e2a) Sub-national (provinces/states) 2e2b) Districts 2e2c) Clinics 2e2d) Clinicians/care providers 2e2e) NGOs/other organizations 2e3) Hard copies distributed: 1= Yes 2= No (Go to Q2e4) If Yes , to whom/at what level: Yes No 2e3a) Sub-national (provinces/states) 2e3b) Districts 2e3c) Clinics 2e3d) Clinicians/care providers 2e3e) NGOs/other organizations AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 2/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: I - STI strategy (Continued ) 2e4) Trainings/oral presentations or other forms of face-to-face meetings: 1= Yes 2= No (Go to Q2e5) If Yes , to whom/at what level: Yes No 2e4a) Sub-national (provinces/states) 2e4b) Districts 2e4c) Clinics 2e4d) Clinicians/care providers 2e4e) NGOs/other organizations 2e5) Other: 1= Yes 2= No (Go to Q3) 2e5s) If Other= Yes , please provide a short description of the process: 3. Has the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 been used to guide any new or updated STI policies or programmatic activities? 1= Yes 2= No 3= Don't know 4= Data not available 4. Has the WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016 been disseminated within your country and how? 1= Yes 2= No, not formally distributed (Go to Q5) 4a) Posted on website: 1= Yes 2= No (Go to Q4b) 4as) If Yes , please provide the link: 4b) Email distribution: 1= Yes 2= No (Go to Q4c) If Yes , to whom/at what level: Yes No 4b1) Sub-national (provinces/states) 4b2) Districts 4b3) Clinics 4b4) Clinicians/care providers 4b5) NGOs/other organizations 4c) Hard copies distributed: 1= Yes 2= No (Go to Q4d) If Yes , to whom/at what level: Yes No 4c1) Sub-national (provinces/states) 4c2) Districts 4c3) Clinics 4c4) Clinicians/care providers 4c5) NGOs/other organizations AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 3/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: I - STI strategy (Continued ) 4d) Trainings/oral presentations or other forms of face-to-face meetings: 1= Yes 2= No (Go to Q4e) If Yes , to whom/at what level: Yes No 4d1) Sub-national (provinces/states) 4d2) Districts 4d3) Clinics 4d4) Clinicians/care providers 4d5) NGOs/other organizations 4e) Other: 1= Yes 2= No (Go to Q5) 4es) If Other= Yes , please provide a short description of the process: II - STI treatment guidelines 5. Are you familiar with (have copies or have the links to) the 2016 WHO STI Treatment Guidelines? Yes No 5a) Neisseria gonorrhoeae (gonorrhoea) 5b) Chlamydia trachomatis (chlamydia) 5c) Herpes simplex virus: (Genital herpes) 5d) Treponema pallidum (syphilis) 6. Does the country have formal national STI treatment guidelines? 1= Yes 2= No (Go to Q6d) If Q6= Yes, Complete Q6a, Q6b, Q6c and Go to Q7. If Q6= No, Complete Q6d and Go to Q7. 6a) If Q6= Yes , when was it last updated? (year) 9999 if Don't know or Data not available 6b) If Q6= Yes , were the 2016 WHO STI treatment guidelines used as a reference for the development or update of the national STI guidelines? 1= Yes 2= No 3= Don't know 4= Data not available 6c) If Q6= Yes , specify which reference documents have been used to develop national STI treatment guidelines? Yes No 6c1) WHO STI treatment guidelines 6c2) US CDC STD treatment guidelines 6c3) STI treatment guidelines from a neighbour country 6c4) International Union of STI treatment guidelines 6c5) BASHH Guidelines - British Association for Sexual Health and HIV 6c6) Other 6c6s) If Other= Yes , please specify: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 4/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: II - STI treatment guidelines (Continued ) 6d) If Q6= No , specify which documents are used to guide treatment of STIs? Yes No 6d1) WHO STI treatment guidelines 6d2) US CDC STD treatment guidelines 6d3) STI treatment guidelines from a neighbour country 6d4) International Union of STI treatment guidelines 6d5) BASHH Guidelines - British Association for Sexual Health and HIV 6d6) Other 6d6s) If Other= Yes , please specify: 7. Have any STI treatment guidelines been disseminated in your country and how? 1= Yes 2= No, not formally distributed (Go to Q8) 7a) Posted on website: 1= Yes 2= No (Go to Q7b) 7as) If Yes , please provide the link: 7b) Email distribution: 1= Yes 2= No (Go to Q7c) If Yes , to whom/at what level: Yes No 7b1) Sub-national (provinces/states) 7b2) Districts 7b3) Clinics 7b4) Clinicians/care providers 7b5) NGOs/other organizations 7c) Hard copies distributed: 1= Yes 2= No (Go to Q7d) If Yes , to whom/at what level: Yes No 7c1) Sub-national (provinces/states) 7c2) Districts 7c3) Clinics 7c4) Clinicians/care providers 7c5) NGOs/other organizations 7d) Trainings/oral presentations or other forms of face-to-face meetings: 1= Yes 2= No (Go to Q7e) If Yes , to whom/at what level: Yes No 7d1) Sub-national (provinces/states) 7d2) Districts 7d3) Clinics 7d4) Clinicians/care providers 7d5) NGOs/other organizations 7e) Other: 1= Yes 2= No (Go to Q8) 7es) If Other= Yes , please provide a short description of the process: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 5/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: III - National STI priorities 8. Please designate the priority level of each of these interventions in your country for STI control and prevention. Choose one priority level for programme implementation (High, Medium, Low, Not a Priority or Not Done) per intervention: INTERVENTION HIGH MEDIUM LOW NOT A PRIORITY OR NOT DONE 8a) Elimination of mother-to-child Transmission of HIV & syphilis 8b) HPV Vaccine for young women 8c) Condom distribution 8d) STI syndromic management 8e) STI surveillance and monitoring 8f) Antimicrobial resistance monitoring of gonococcal isolates 8g) STI screening among high-risk populations of MSM and sex workers 8h) STI screening conducted among persons with HIV 8i) Provision of STI services for adolescents IV - Location of STI care services 9. Sexually transmitted infection care services are provided in which of the following clinical settings? Note: Presence of STI care services is defined as presence of a health professional capable of STI management, including diagnosis (syndromic or etiological), treatment, counseling, and partner management If Yes , estimated percentage of all STI care delivered in this setting Yes No 999 if Don't know or Data not available 9a) Primary care clinics % 9b) Reproductive health clinics % 9c) HIV clinics % 9d) Family planning clinics % 9e) Antenatal/postnatal care clinics % 9f) Specialized STI clinics % 9g) Key population services (MSM, sex workers) % 9h) Adolescent healthcare services % 9i) Prison settings % AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 6/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: V - Surveillance systems 10. Is STI surveillance or monitoring being done in your country? 1= Yes 2= No (Go to Q11) 10a) If Yes , Which surveillance or monitoring elements are included? Yes No 10a1) Periodic STI prevalence survey among general and high risk populations 10a2) Etiologic assessment of STI syndromes 10a3) STI case reporting 10b) If Q10a3= Yes , which STIs are reported at different levels of the health system? a- Universal b- STI Clinics c- Sentinel Sites d- Private Sector e- Laboratories Yes No Yes No Yes No Yes No 10b1) Syndrome: Urethral discharge 10b2) Syndrome: Genital Ulcer Disease 10b3) Syndrome: Vaginal discharge Yes No 10b4) Etiologies: Syphilis 10b5) Etiologies: Gonorrhoea 10b6) Etiologies: Chlamydia 10b7) Etiologies: Trichomoniasis 10b8) Etiologies: Syphilis in pregnant women 10c) Is STI surveillance or monitoring integrated within the national health information system (NHIS)? 1= Yes 2= No 10d) Is the surveillance data disaggregated by: Yes No 10d1) age: 10d2) sex: 10d3) location: 10d4) population: 11. Is the country entering HIV indicators into the UNAIDS Global AIDS Monitoring System? 1= Yes 2= No (Go to Q13) AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 7/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: V - Surveillance systems (Continued ) 12. Is the country entering STI indicators into the UNAIDS Global AIDS Monitoring System? 1= Yes (Complete Q12a to Q12h and Go to Q13) 2= No (Go to Q12i) If Q12= Yes, check which STI indicators are entered into the UNAIDS Global AIDS Monitoring System: Yes No 12a) Syphilis screening coverage among pregnant women in antenatal care clinics 12b) Syphilis positivity among pregnant women in antenatal care clinics 12c) Syphilis treatment coverage among pregnant women testing positive in antenatal care clinics 12d) Congenital syphilis case rate 12e) Syphilis screening and positivity in MSM 12f) Syphilis screening and positivity in sex workers 12g) Urethral discharge case rate in men 12h) Gonorrhoea case rate in men 12i) If Q12= No , why? VI - Elimination of Mother to Child Transmission of HIV and Syphilis 13. Is there a national strategy for the Elimination of Mother-to-Child Transmission of HIV and Syphilis? 1= Yes 2= No (Go to Q14) 3= Yes, but for HIV only (Go to Q14) 13a) If Yes , add and/or provide link to the CS case definition 13b) If Yes, is the country planning to validate elimination of vertical transmission of both HIV and syphilis or Path to Elimination? 1= Yes 2= No 13c) If Yes, which year is country planning to apply for WHO validation of elimination (EMTCT) or Path to Elimination? 2 0 99 if Don't know or Data not available 14. Is there a national policy for screening pregnant women for HIV? 1= Yes 2= No (Go to Q15) 14a) If Yes , how many times during the pregnancy? 14b) If Yes, is the country screening at delivery? 1= Yes 2= No 15. Is there a national policy for screening pregnant women for syphilis? 1= Yes 2= No 15a) If Yes , how many times during the pregnancy? 15b) If Yes, is the country screening at delivery? 1= Yes 2= No AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 8/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: VI - Elimination of Mother to Child Transmission of HIV and Syphilis (Continued) 16. Are pregnant women routinely screened for any of the following STIs? Yes No 16a) HIV 16b) Syphilis 16c) Gonorrhoea 16d) Chlamydia 16e) Trichomoniasis 16f) Human papillomavirus (HPV) 16g) Genital herpes 16h) Hepatitis B 16i) Hepatitis C 16h) Other 16hs) If Other= Yes , please specify: 17. Are rapid syphilis tests used in antenatal care (ANC) clinics? 1= Yes 2= No (Go to Q18) 17a) If your country uses rapid syphilis tests in ANC have you experienced stockouts of test kits? 1= Yes 2= No 18. Are dual HIV/syphilis tests used in antenatal care (ANC) clinics? 1= Yes 2= No (Go to Q19) 18a) If Yes, please specify brand: 18b) If Yes, please specify price: VII - Screening, Diagnosis, and Treatment of STIs 19. Are key populations of men who have sex with men (MSM) and sex workers screened for any of the following STIs? 1- MSM 2- Sex workers Yes No Yes No 19a) HIV 19b) Syphilis 19c) Gonorrhoea 19d) Chlamydia 19e) Trichomoniasis 19f) Human papillomavirus (HPV) 19g) Genital herpes 19h) Hepatitis B 19i) Hepatitis C 19j) Other 19js) If Other= Yes , please specify: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 9/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: VII - Screening, Diagnosis, and Treatment of STIs (Continued) 20. Which of the following diagnostic tests are available for STI diagnosis for the general population? Yes No 20a) HIV 20b) Syphilis 20c) Gonorrhoea 20d) Chlamydia 20e) Trichomoniasis 20f) Human papillomavirus (HPV) 20g) Genital herpes 20h) Hepatitis B 20i) Hepatitis C 20j) Other 20js) If Other= Yes , please specify: 21. Have any studies been conducted in the country to identify the common etiologies of STI syndromes (urethral discharge, vaginal discharge, genital ulcer disesase)? 1= Yes 2= No (Go to Q22) 21a) Year of the latest version of the study: 9999 if Don't know or Data not available 21b1) Provide WEB Link if Available : OR 21b2) Check the box if WEB link is Not available: 22. What are the recommended medications used for urethral discharge? Yes No 22a) Acyclovir 22b) Azithromycin 22c) Benzathine penicillin 22d) Ceftriaxone 22e) Cefixime 22f) Doxycycline 22g) Metronidazole 22h) Other 22hs) If Other= Yes , please specify: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 10/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: VII - Screening, Diagnosis, and Treatment of STIs (Continued ) 23. What are the recommended medications used for vaginal discharge? Yes No 23a) Acyclovir 23b) Azithromycin 23c) Benzathine penicillin 23d) Ceftriaxone 23e) Cefixime 23f) Doxycycline 23g) Metronidazole 23h) Other 23hs) If Other= Yes , please specify: 24. What are the recommended medications used for genital ulcer disease? Yes No 24a) Acyclovir 24b) Azithromycin 24c) Benzathine penicillin 24d) Ceftriaxone 24e) Cefixime 24f) Doxycycline 24g) Metronidazole 24h) Other 24hs) If Other= Yes , please specify: 25. Which medications are on the national formulary or procurement list for treatment of STIs? Yes No 25a) Acyclovir 25b) Azithromycin 25c) Benzathine penicillin 25d) Ceftriaxone 25e) Cefixime 25f) Doxycycline 25g) Metronidazole 25h) Other 25hs) If Other= Yes , please specify: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 11/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: VII - Screening, Diagnosis, and Treatment of STIs (Continued ) 26. Has the country experienced stockouts of STI medications? If Yes , year when stockout was identified (9999 if Don't know or Data not available ) Yes No First identified Last identified 26a) Acyclovir 26b) Azithromycin 26c) Benzathine penicillin 26d) Ceftriaxone 26e) Cefixime 26f) Doxycycline 26g) Metronidazole 26h) Crystalline penicillin 26i) Other 26is) If Other= Yes , please specify: VIII - Surveillance for Antimicrobial Resistance (AMR) in Gonorrhoea/Gonococcal isolates 27. Is antimicrobial susceptibility testing performed by your national reference lab? 1= Yes 2= No (Go to Q29) 27a) Is antimicrobial susceptibility testing for gonorrhoea performed by your national reference lab? 1= Yes 2= No (Go to Q29) 27as) If Yes , please, provide name of national reference lab: 27b) If Yes, were the results used to inform treatment schemes? 1= Yes 2= No 28. Is surveillance of gonococcal antimicrobial susceptibility conducted in your country? 1= Yes 2= No (Go to Q29) 28a) Year of latest study of susceptibility testing: 9999 if Don't know or Data not available 28b) Name of test method: AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 12/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: IX. HPV vaccination, screening, diagnosis, and treatment 29. Is the human papillomavirus (HPV) vaccine included in the national immunization schedule? 1= Yes 2= No (Go to Q30) 29a) If Q29= Yes , please provide the WEB link of National immunization schedule: 29a1) Provide WEB link if Available : OR 29a2) Check the box if WEB link is Not available: 29b) If Q29= Yes , to whom and at what age? 29b1) Adolescent girls: 1= Yes 2= No 29b2) Adolescent girls and boys: 1= Yes 2= No 29b3) Age range for HPV vaccine: 99 if Don't know 29b4) Is the human papillomavirus (HPV) vaccine for PLHIV included in the national immunization schedule? 1= Yes 2= No 29b4a) If Yes, what is the age range for PLHIV: 99 if Don't know 29b5) Is the human papillomavirus (HPV) vaccine for MSM included in the national immunization schedule? 1= Yes 2= No 29b5a) If Yes, what is the age range for MSM: 99 if Don't know 30. Does your country have a national cancer registry that includes cervical cancer? 1= Yes 2= No (Go to Q31) Yes No 30a) Population based 30b) Hospital based 30c) National 30d) Sub-National 31. Is screening for cervical cancer available for general populations of women between the ages of 35 and 55? 1= Yes 2= No (Go to Q33) AAC World Health Evaluation of the Global STI Strategy: Country STI Survey Page 13/13 Organization STI Activities Assessment at Country Level V1.0 (11 Jun 2019) PROJECT ID: Date form completed: A 6 5 9 9 6 Day Month Year 2 0 1 9 Name of Country: IX. HPV vaccination, screening, diagnosis, and treatment (Continued) 32. If cervical cancer screening is available, which tests are used? Yes No 32a) PAP smear/test 32b) HPV test 32bs) If HPV test=Yes , please provide which HPV test is used: 32c) Acetic acid testing 32d) Visual inspection only 32e) Other 32es) If Other= Yes , please specify: 33. What treatments are used for patients with abnormal cervical screening results (pre-cancerous lesions)? Yes No 33a) Thermo ablation 33b) Cryotherapy (liquid nitrogen) 33c) Loop Electrosurgical Excision Procedure or conization 33d) Surgical removal with other procedure 33e) Other 33es) If Other= Yes , please specify: X - Technical assistance 34.Is the country in need to WHO technical assistance? 1= Yes 2= No (Go to Q31) If Yes , on which areas? Yes No 34a) Development of National STI strategy 34b) Development of National STI treatment guidelines 34c) STI care services 34d) STI surveillance 34e) EMTCT of HIV and syphilis 34f) Screening, diagnosis and treatment 34g) Surveillance in AMR resistance in Gonorrhoea 34h) HPV vaccination, screening, diagnosis and treatment 35.What other technical partners / agencies are supporting you in the STI prevention and control services, and in which particular area? 36.What is the main source of funding support for implementation of STI-related prevention and control programmes in country? (Date and Sign questionnaire) To be completed by Responder: To be completed by Data Entry Operator: Name: Name: Signature: Signature: Day Month Year Day Month Year Date: 2 0 1 9 Date: 2 0 1 9 Annex 4. TEXT FOR INCLUSION IN DATA COLLECTION FORMS Data are the basis for all sound public health actions and the benefits of data sharing are widely recognized, including scientific and public health benefits. Whenever possible, WHO wishes to promote the sharing of health data, including but not restricted to surveillance and epidemiological data. In this connection, and without prejudice to information sharing and publication pursuant to legally binding instruments, by providing data to WHO, the [Ministry of Health][other responsible governmental entity] of [Country]: Confirms that all data to be supplied to WHO (including but not limited to the types listed in Annex 3) hereunder have been collected in accordance with applicable national laws, including data protection laws aimed at protecting the confidentiality of identifiable persons; Agrees that WHO shall be entitled, subject always to measures to ensure the ethical and secure use of the data, and subject always to an appropriate acknowledgement of [Country]: - to publish the data, stripped of any personal identifiers (such data without personal identifiers being hereinafter referred to as “the Data”) and make the Data available to any interested party on request (to the extent they have not, or not yet, been published by WHO) on terms that allow non-commercial, not-for-profit use of the Data for public health purposes (provided always that publication of the Data shall remain under the control of WHO); - to use, compile, aggregate, evaluate and analyse the Data and publish and disseminate the results thereof in conjunction with WHO’s work and in accordance with the Organization’s policies and practices. Except where data sharing and publication is required under legally binding instruments (IHR, WHO Nomenclature Regulations 1967, etc.), the [Ministry of Health][other responsible governmental entity] of [Country] may in respect of certain data opt out of (any part of) the above, by notifying WHO thereof in writing at the following address, provided that any such notification shall clearly identify the data in question and clearly indicate the scope of the opt- out (in reference to the above), and provided that specific reasons shall be given for the opt out. [address] Saatja: Triin Uusberg <[email protected]> Saadetud: 20.06.2019 13:39 Adressaat: Mall Hiet <[email protected]> Koopia: Tiina Drell <[email protected]> Teema: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893 Manused: STI Questionnaire 2019 - EST.pdf; STI_Questionnaire_en.pdf; Annex_eng.pdf Palun registreerige ning suunake Tiina Drellile. Aitäh, Triin From: Heli Laarmann <[email protected]> Sent: Thursday, June 20, 2019 1:10 PM To: Triin Uusberg <[email protected]>; Tiina Drell <[email protected]> Cc: Elen Ohov <[email protected]> Subject: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893 Tiina, palun korralda vastamine. Kas soovid materjale ka Delta kaudu? Ma ise arvan, et ajaloo huvides oleks hea, kui see saab ka Delta kaudu edastatud ja sellele seal reageeritud. Heli From: Triin Uusberg <[email protected]> Sent: Thursday, June 20, 2019 10:07 AM To: Heli Laarmann <[email protected]> Cc: Elen Ohov <[email protected]> Subject: FW: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893 Kas tahad ka Delta kaudu saada või vastate niisama? Triin From: Olga Fradkina <[email protected]> Sent: Wednesday, June 19, 2019 11:15 PM To: Elen Ohov <[email protected]> Cc: Andre Pung <[email protected]>; Marge Reinap <[email protected]>; Märt Volmer <[email protected]>; Triin Uusberg <[email protected]> Subject: Evaluation of the Global STI Strategy: Country STI Survey CRM:0056893 Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachments may be included. Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes. Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalbüro für Europa См. прикрепленные письма от Европейского регионального бюро Всемирной организации здравоохранения (один или несколько прикрепленных файлов).
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel